The commercial path toward clinical life extension has received a major boost as senior leaders from the U.S. Food and Drug Administration (FDA) formally announced strategies to integrate anti-aging medicine into the agency’s primary regulatory science agenda. Speaking at a prominent industry panel, regulators outlined new frameworks designed to help biotechnology developers evaluate therapeutics targeting multiple age-related chronic diseases simultaneously. This historic shift aims to dismantle traditional single-disease testing bottlenecks, drastically accelerating the approval timeline for cutting-edge cellular repair protocols and senolytic treatments.
About the Author
